Press Release

Chengdu, China，Sep. 11th, 2017, HitGen Ltd announced that the company has entered into a research collaboration with Takeda Pharmaceutical Company Limited to discover novel small molecule leads for multiple targets in Takeda’s therapeutic areas of interest. According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively to Takeda. Under the terms of the agreement, HitGen will receive upfront compensation, and be eligible for milestone payments from Takeda. Specific financial details were not disclosed.

ATLANTA, GA and BOTHELL, WA—(Marketwired) – September 5, 2017 - Cocrystal Pharma, Inc. (OTCQB: COCP) today announced that it has entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company to develop small molecule drug candidates against several undisclosed targets.

Chengdu, China，7th August, 2017, HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with LEO Pharma A/S , to discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from LEO Pharma.

Chengdu, China，14th August, 2017, HitGen Ltd announced that the company has entered into a multi-target multi-year collaboration with Aduro Biotech Inc , to discover novel small molecule leads for multiple therapeutic targets of interest to Aduro. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library (DEL) design, synthesis and screening to discover novel leads which will be licensed exclusively to Aduro. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from Aduro.

Chengdu, China, April 24th 2017: HitGen Ltd., a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced today a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

Chengdu, China, April 17th, 2017, HitGen Ltd. is pleased to announce that the company has entered into a multi-year research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to build and screen novel DNA-encoded libraries (DELs) in order to potentially discover unique small molecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s drug discovery efforts. In addition, HitGen will screen their own DELs, consisting of billions of compounds, against a selected number of Pfizer’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to Pfizer for further research and development. Pfizer will fund the research at HitGen.

Chengdu, China，22nd March, 2017, HitGen Ltd announced that the company has entered into a collaboration with MSD, known as Merck in the United States and Canada, to discover novel chemical leads for multiple therapeutic targets of interest to MSD. According to this agreement, HitGen will deploy its core technology platform, based on DNA-encoded library design, synthesis and screening.. The novel leads identified will be licensed exclusively to MSD. Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from MSD.

Cancer Research UK, Cancer Research Technology (CRT), the charity’s commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

September 22, 2016, Chengdu – Academician Sang Guowei, the Vice Chairperson of the National People’s Congress of the Peoples’ Republic of China, Chief Engineer of National Major Innovative Drug Projects as well as an Academician of the Chinese Academy of Engineering, accompanied by officials from Sichuan Provincial and Chengdu Municipal Government visited HitGen Ltd. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to Professor Sang Guowei.

Chengdu, China, September 22, 2016, HitGen Ltd., a privately held biotech company focused on technology for effective and efficient molecular discovery, announced today a multi-target global collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which has been facilitated by Johnson & Johnson Innovation. This collaboration is to discover potential new therapies in areas of strategic interest to Janssen, especially in the areas of oncology and metabolics.